Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy

Kidney International

Volumn 80, Issue 3, 2011, Pages 302-309

  Dauchy, Frédéric Antoine ^a   Lawson Ayayi, Sylvie ^b   De La Faille, Renaud ^c   Bonnet, Fabrice ^a,b   Rigothier, Claire ^c   Mehsen, Nadia ^c   Miremont Salamé, Ghada ^d   Cazanave, Charles ^a   Greib, Carine ^a   Dabis, Francois ^b   Dupon, Michel ^a  

^a HÔPITAL PELLEGRIN   (France)

^b INSERM   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

antiretroviral therapy; HIV; kidney tubule; phosphate; proximal tubule

Indexed keywords

ABACAVIR; ACETYLSALICYLIC ACID; ACICLOVIR; ADEFOVIR; ALBUMIN; AMPHOTERICIN B; ANTIRETROVIRUS AGENT; ATAZANAVIR; BETA 2 MICROGLOBULIN; CIDOFOVIR; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; GANCICLOVIR; INDINAVIR; LOPINAVIR; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; URIC ACID; ZIDOVUDINE;

ADULT; AGE; ALBUMINURIA; ANTIVIRAL THERAPY; ARTICLE; BETA 2 MICROGLOBULIN URINE LEVEL; CHRONIC HEPATITIS; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSURIA; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPOPHOSPHATEMIC RICKETS; KIDNEY DYSFUNCTION; KIDNEY PROXIMAL TUBULE; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; METABOLIC ACIDOSIS; PHOSPHATE BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; PROXIMAL RENAL TUBULAR DYSFUNCTION; RISK FACTOR; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; VIRUS LOAD;

EID: 79960404943     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.124     Document Type: Article

References (47)

1. Palella Jr FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860. (Pubitemid 28135961)
2. Mocroft A, Kirk O, Gatell J et al. Chronic renal failure among HIV-1-infected patients. AIDS 2007; 21: 1119-1127. (Pubitemid 46763282)
3. Mocroft A, Kirk O, Reiss P et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24: 1667-1678.
4. Choi AI, Li Y, Parikh C et al. Long-term clinical consequences of acute kidney injury in the HIV-infected. Kidney Int 2010; 78: 478-485.
5. Verhelst D, Monge M, Meynard JL et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002; 40: 1331-1333. (Pubitemid 35403147)
6. Karras A, Lafaurie M, Furco A et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36: 1070-1073. (Pubitemid 36513295)
7. Gaspar G, Monereo A, Garcia-Reyne A et al. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution. AIDS 2004; 18: 351-352. (Pubitemid 38253468)
8. Malik A, Abraham P, Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment-case report and review of literature. J Infect 2005; 51: E61-E65. (Pubitemid 40984370)
9. Tebas P, Powderly WG, Claxton S et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000; 14: F63-F67. (Pubitemid 30182458)
10. Cazanave C, Dupon M, Lavignolle-Aurillac V et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008; 22: 395-402.
11. Labarga P, Barreiro P, Martin-Carbonero L et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009; 23: 689-696.
12. Fux CA, Christen A, Zgraggen S et al. Effect of tenofovir on renal glomerular and tubular function. AIDS 2007; 21: 1483-1485. (Pubitemid 46988011)
13. Levey AS, Eckardt KU, Tsukamoto Y et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-2100. (Pubitemid 41623371)
14. Horberg M, Tang B, Towner W et al. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr 2010; 53: 62-69.
15. Deti EK, Thiebaut R, Bonnet F et al. Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. HIV Med 2009; 11: 308-317.
16. Choi AI, Shlipak MG, Hunt PW et al. HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. AIDS 2009; 23: 2143-2149.
17. Szczech LA, Gange SJ, van der Horst C et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 2002; 61: 195-202. (Pubitemid 34075147)
18. Lignac GOE. Storis der cystine-stofwisseling byj kinderen. Ned Tijdschr Geneeskd 1924; 68: 2987-2995.
19. Fanconi G. Der Frü hinfantile Nephrotischglyko-surische Zwergwuchs Mit Hypophosphätamischer Rachitis. Jahrbuch Ninderhrilkunde 1936; 147: 299.
20. Izzedine H, Launay-Vacher V, Isnard-Bagnis C et al. Drug-induced Fanconi's syndrome. Am J Kidney Dis 2003; 41: 292-309. (Pubitemid 36152447)
21. Norden AG, Scheinman SJ, Deschodt-Lanckman MM et al. Tubular proteinuria defined by a study of Dent's (CLCN5 mutation) and other tubular diseases. Kidney Int 2000; 57: 240-249. (Pubitemid 30227771)
22. Breton G, Alexandre M, Duval X et al. Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1. Scand J Infect Dis 2004; 36: 527-528. (Pubitemid 39089222)
23. Welz T, Childs K, Ibrahim F et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 2010; 24: 1923-1928.
24. Tanji N, Tanji K, Kambham N et al. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 2001; 32: 734-740. (Pubitemid 32726898)
25. Meier P, Dautheville-Guibal S, Ronco PM et al. Cidofovir-induced end-stage renal failure. Nephrol Dial Transplant 2002; 17: 148-149. (Pubitemid 34093027)
26. Ray AS, Cihlar T, Robinson KL et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006; 50: 3297-3304. (Pubitemid 44527501)
27. Van Rompay KK, Brignolo LL, Meyer DJ et al. Biological effects of shortterm or prolonged administration of 9-[2-(phosphonomethoxy)propyl] adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004; 48: 1469-1487. (Pubitemid 38544348)
28. Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS 2008; 22: 99-103. (Pubitemid 351252586)
29. Rodriguez-Novoa S, Labarga P, D'Avolio A et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS 2010; 24: 1064-1066.
30. Kiser JJ, Aquilante CL, Anderson PL et al. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr 2008; 47: 298-303. (Pubitemid 351619414)
31. Zimmermann AE, Pizzoferrato T, Bedford J et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42: 283-290. (Pubitemid 43054205)
32. Gagnieu MC, Barkil ME, Livrozet JM et al. Population pharmacokinetics of tenofovir in AIDS patients. J Clin Pharmacol 2008; 48: 1282-1288.
33. Rodriguez-Novoa S, Labarga P, Soriano V et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 2009; 48: 108-116.
34. Gupta SK, Eustace JA, Winston JA et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40: 1559-1585. (Pubitemid 40720806)
35. Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS 2009; 23: 1971-1975.
36. Goicoechea M, Liu S, Best B et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008; 197: 102-108. (Pubitemid 351263473)
37. Kearney BP, Mathias A, Mittan A et al. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr 2006; 43: 278-283. (Pubitemid 44674007)
38. Kiser J, Carten M, Wolfe P et al. Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV-Infected Patients. Abstract No. 570. CROI: Denver, 2006.
39. Jullien V, Treluyer JM, Rey E et al. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. Antimicrob Agents Chemother 2005; 49: 3361-3366. (Pubitemid 41060583)
40. Wei A, Burns GC, Williams BA et al. Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int 2003; 64: 1462-1471. (Pubitemid 37153814)
41. Winston JA, Bruggeman LA, Ross MD et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 2001; 344: 1979-1984. (Pubitemid 32568152)
42. Thiebaut R, Morlat P, Jacqmin-Gadda H et al. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidemiologie du SIDA en Aquitaine (GECSA). AIDS 2000; 14: 971-978. (Pubitemid 30336057)
43. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470. (Pubitemid 29135798)
44. Methven S, MacGregor MS, Traynor JP et al. Assessing proteinuria in chronic kidney disease: protein-creatinine ratio versus albumin-creatinine ratio. Nephrol Dial Transplant 2010; 25: 2991-2996.
45. Samarawickrama A, Nambiar K, Gilleece Y et al. The Value of Urine Protein/Creatinine and albumin/Creatinine Ratios in Assessing Renal Disease in HIV Infection. Abstract No. 570. CROI: San Francisco, 2010.
46. Bijvoet OL. Relation of plasma phosphate concentration to renal tubular reabsorption of phosphate. Clin Sci 1969; 37: 23-36.
47. Laroche M, Boyer JF, Jahafar H. et al. Normal FGF23 levels in adult idiopathic phosphate diabetes. Calcif Tissue Int 2009; 84: 112-117.